×
COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome i...
https://doi.org/10.1002/jmv.26078
Journal of Medical Virology; Chakraborty C, Sharma AR et. al.

May 27th, 2020 - COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physic...

Sars-CoV-2 in the context of past coronaviruses epidemics: Consideration for prenatal c...
https://doi.org/10.1002/pd.5759
Prenatal Diagnosis; Lambelet V, Vouga M et. al.

May 25th, 2020 - Since December 2019, the novel SARS-CoV-2 outbreak has resulted in millions of cases and more than 200,000 deaths worldwide. The clinical course among non-pregnant women has been described but data about potential risks for women and their fetus remain scarce. The SARS and MERS epidemics were responsible for miscarriages, adverse fetal and neonatal outcomes and maternal deaths. For COVID-19 inf...

Trials and tribulations: so many potential treatments, so few answers.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245574
International Orthopaedics; Gazendam A, Nucci N et. al.

May 24th, 2020 - The purpose of this review is to quantify the landscape of current clinical trials ongoing for therapies in the treatment of COVID-19. A secondary purpose is to examine the relationship between public and scientific interests in potential therapies for COVID-19. A systematic search of clinicaltrials.gov was undertaken on April 22, 2020, to identify all currently registered clinical trials inves...

Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multipl...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205724
International Immunopharmacology; Saghazadeh A, Rezaei N

May 15th, 2020 - The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient ...

What's the Latest on COVID-19 Medications and Vaccination in the UK?
https://www.medscape.com/viewarticle/930581

May 14th, 2020 - Editor's note, 18th May 2020: This article was updated for clarity. The race to find treatments and other therapeutic options such as vaccines for COVID-19 is on, and success is still a long way off - at least not before the start of 2021, according to Stuart Ralston, professor of rheumatology at the Centre for Genomic and Experimental Medicine, University of Edinburgh. He is also chairman of t...

COVID-19: progression of disease and intravascular coagulation - present status and fut...
https://doi.org/10.1515/cclm-2020-0502
Clinical Chemistry and Laboratory Medicine; Harenberg J, Favaloro E

May 13th, 2020 - The timely and accurate diagnosis of infection with severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), remains the cornerstone of efforts to provide appropriated treatment for patients, to limit further spread of the virus and ultimately to eliminate the virus from the human society. We focus this article on (a) developments fo...

Platelet functions and activities as potential hematologic parameters related to Corona...
https://doi.org/10.1080/09537104.2020.1762852
Platelets Salamanna F, Maglio M et. al.

May 12th, 2020 - Coronavirus disease 2019 (COVID-19) is a new infectious disease that currently lacks standardized and established laboratory markers to evaluate its severity. In COVID-19 patients, the number of platelets (PLTs) and dynamic changes of PLT-related parameters are currently a concern. The present paper discusses the potential link between PLT parameters and COVID-19. Several studies have identifie...

Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205369
Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie; Lother SA, Abassi M et. al.

May 9th, 2020 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 causing the coronavirus disease (COVID-19) pandemic. Currently, there is a lack of evidence-based therapies to prevent COVID-19 following exposure to the virus, or to prevent worsening of symptoms following confirmed infection. We describe the design of a clinical trial of hydroxychloroquine for post-expos...

Convalescent plasma in Covid-19: Possible mechanisms of action.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198427
Autoimmunity Reviews; Rojas M, Rodríguez Y et. al.

May 7th, 2020 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current sit...

Medical treatment options for COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235633
European Heart Journal. Acute Cardiovascular Care; Delang L, Neyts J

May 4th, 2020 - Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus disease 2019. Unfortunately, no drugs have been approved yet to treat infections with human coronaviruses. As it will take years to develop new...

Treatment for emerging viruses: Convalescent plasma and COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194745
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for HaemApheresis; Brown BL, McCullough J

Apr 29th, 2020 - Use of convalescent plasma transfusions could be of great value in the current pandemic of coronavirus disease (COVID-19), given the lack of specific preventative and therapeutic options. This convalescent plasma therapy is of particular interest when a vaccine or specific therapy is not yet available for emerging viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wh...

Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Consideratio...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188032
Therapeutic Drug Monitoring; Elens L, Langman LJ et. al.

Apr 18th, 2020 - COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-coronavirus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppre...

Individual risk management strategy and potential therapeutic options for the COVID-19 ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139252
Clinical Immunology (Orlando, Fla.); Gasmi A, Noor S et. al.

Apr 10th, 2020 - It is an ugly fact that a significant amount of the world's population will contract SARS-CoV-II infection with the current spreading. While a specific treatment is not yet coming soon, individual risk assessment and management strategies are crucial. The individual preventive and protective measures drive the personal risk of getting the disease. Among the virus-contracted hosts, their differe...

CDC Removes Unusual Guidance to Doctors About Drug Favored by Trump
https://www.medscape.com/viewarticle/928311

Apr 7th, 2020 - WASHINGTON (Reuters) - The U.S. Centers for Disease Control and Prevention has removed from its website highly unusual guidance informing doctors on how to prescribe hydroxychloroquine and chloroquine, drugs recommended by President Donald Trump to treat the coronavirus. The move comes three days after Reuters reported that the CDC published key dosing information involving the two antimalarial...

Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128600
International Journal of Antimicrobial Agents; Praveen D, Puvvada RC et. al.

Apr 7th, 2020 - The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib...

CDC removes unusual guidance to doctors about drug favored by Trump
https://www.reuters.com/article/us-health-coronavirus-usa-cdcguidance/cdc-removes-unusual-guidance-to-doctors-about-drug-favored-by-trump-idUSKBN21P39R

Apr 7th, 2020 - WASHINGTON (Reuters) - The U.S. Centers for Disease Control and Prevention has removed from its website highly unusual guidance informing doctors on how to prescribe hydroxychloroquine and chloroquine, drugs recommended by President Donald Trump to treat the coronavirus. A woman holds a hydroxychloroquine prescription in Seattle, Washington, U.S. March 31, 2020. REUTERS/Lindsey Wasson The move ...

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127386
Antiviral Research; Choy KT, Wong AY et. al.

Apr 6th, 2020 - An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, l...

SARS serum neutralizing antibodies may inform the treatment of COVID-19
https://www.mdedge.com/pulmonary-health-hub/article/220108/coronavirus-updates/sars-serum-neutralizing-antibodies-may?channel=63993
Mark S. Lesney

Apr 2nd, 2020 - The immune responses of specific antibodies were maintained in more than 90% of recovered SARS-CoV patients for 2 years, raising the likelihood that the similarly behaving SARS-CoV-2 might provoke the same response, according to an online communication published in the Journal of Microbiology, Immunology and Infection. Courtesy NIAID-RML The authors cited a cohort study of convalescent SARS-CoV.

Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
https://doi.org/10.2174/1871523019999200228100917
Anti-inflammatory & Anti-allergy Agents in Medicinal Chemistry; Carradori S

Mar 27th, 2020 - Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?|2020|Carradori S,|

U.S. drugmaker Pfizer pauses new studies due to coronavirus pandemic
https://www.reuters.com/article/us-health-coronavirus-pfizer/u-s-drugmaker-pfizer-pauses-new-studies-due-to-coronavirus-pandemic-idUSKBN21C2WD

Mar 25th, 2020 - FILE PHOTO: A logo for Pfizer is displayed on a monitor on the floor at the New York Stock Exchange (NYSE) in New York, U.S., July 29, 2019. REUTERS/Brendan McDermid/File Photo (Reuters) - Pfizer Inc said on Wednesday it was delaying patient recruitment in new and ongoing global trials for three weeks due to the coronavirus outbreak, as drugmakers look to ease the burden on healthcare facilitie...